Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 Omicron-Reference-Cited by-同舟云学术

Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 Omicron

Published:2022-01-21 Issue:7902 Volume:603 Page:693-699
ISSN:0028-0836
Container-title:Nature
language:en
Short-container-title:Nature

Author:

Shuai Huiping^ORCID,Chan Jasper Fuk-Woo^ORCID,Hu Bingjie,Chai Yue,Yuen Terrence Tsz-Tai,Yin Feifei,Huang Xiner^ORCID,Yoon Chaemin,Hu Jing-Chu^ORCID,Liu Huan,Shi Jialu,Liu Yuanchen,Zhu Tianrenzheng,Zhang Jinjin,Hou Yuxin,Wang Yixin,Lu Lu,Cai Jian-Piao,Zhang Anna Jinxia^ORCID,Zhou Jie^ORCID,Yuan Shuofeng,Brindley Melinda A.,Zhang Bao-Zhong,Huang Jian-Dong^ORCID,To Kelvin Kai-Wang^ORCID,Yuen Kwok-Yung^ORCID,Chu Hin^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

https://www.nature.com/articles/s41586-022-04442-5.pdf

Reference42 articles.

1. Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern (WHO, 2021); https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern

2. Cele, S., Jackson, L., Khan, K., Khoury, D. & Sigal, A. Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. Nature https://doi.org/10.1038/s41586-021-04387-1 (2021).

3. Wang, Y. et al. The significant immune escape of pseudotyped SARS-CoV-2 variant Omicron. Emerg. Microbes Infect. 11, 1–5 (2022).

4. Lu, L. et al. Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients. Clin. Infect. Dis. https://doi.org/10.1093/cid/ciab1041 (2021).

5. Dejnirattisai, W. et al. Reduced neutralisation of SARS-CoV-2 Omicron B.1.1.529 variant by post-immunisation serum. Lancet 399, 234–236 (2022).

Cited by 437 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inhibition of multiple SARS-CoV-2 variants entry by Lycium barbarum L. polysaccharides through disruption of spike protein-ACE2 interaction;International Journal of Biological Macromolecules;2024-03

2. Potent and broadly neutralizing antibodies against sarbecoviruses induced by sequential COVID-19 vaccination;Cell Discovery;2024-02-06

3. Multilayer factors associated with excess all-cause mortality during the omicron and non-omicron waves of the COVID-19 pandemic: time series analysis in 29 countries;BMC Public Health;2024-02-02

4. UB-612 pan-SARS-CoV-2 T cell immunity-promoting vaccine protects against COVID-19 moderate-severe disease;iScience;2024-02

5. Immune evasion, infectivity, and fusogenicity of SARS-CoV-2 BA.2.86 and FLip variants;Cell;2024-02